The data obtained suggest that boron clusters bind to the EGFR and have the potential to deliver the conjugated cargo (oligonucleotides or possibly other molecules, including anticancer drugs) to EGFR-overexpressing cancer cells via the EGFR-targeted pathway. The gene discussed is EGFR; the disease is cancer.